Overview

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Status:
Active, not recruiting
Trial end date:
2023-03-07
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory AML. Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose [RP2D]).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen